Financial Analysis: Relay Therapeutics (NASDAQ:RLAY) Vs. LadRx (OTCMKTS:CYTR)
Financial Analysis: Relay Therapeutics (NASDAQ:RLAY) Vs. LadRx (OTCMKTS:CYTR)
Relay Therapeutics (NASDAQ:RLAY – Get Rating) and LadRx (OTCMKTS:CYTR – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations.
接力治疗公司(纳斯达克：RLAY-GET评级)和LadRx(场外交易市场：Cytr-GET评级)都是医疗公司，但哪只股票更好？我们将根据两家公司的机构持股、盈利能力、收益、股息、估值、风险和分析师建议来比较它们的实力。
Risk & Volatility
风险与波动性
Relay Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
Relay Treeutics的贝塔系数为1.01，这意味着其股价的波动性比标准普尔500指数高出1%。相比之下，LadRx的贝塔系数为1.96，这意味着其股价的波动性比标准普尔500指数高96%。
Profitability
盈利能力
This table compares Relay Therapeutics and LadRx's net margins, return on equity and return on assets.
下表比较了Relay Treeutics和LadRx的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Relay Therapeutics | -17,136.40% | -21.42% | -18.77% |
| LadRx | N/A | -67.61% | -45.39% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| 接力治疗学 | -17,136.40% | -21.42% | -18.77% |
| LadRx | 不适用 | -67.61% | -45.39% |
Valuation and Earnings
估值和收益
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Relay Therapeutics | $3.03 million | 821.13 | -$363.87 million | ($2.66) | -7.74 |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | -0.61 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| 接力治疗学 | 303万美元 | 821.13 | -3.6387亿美元 | ($2.66) | -7.74 |
| LadRx | 不适用 | 不适用 | -670万元 | ($0.15) | -0.61 |
LadRx has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
LadRx的收入低于Relay Treeutics，但收益高于Relay Treeutics。Relay治疗公司的市盈率低于LadRx，这表明它目前是两只股票中更负担得起的一只。
Analyst Ratings
分析师评级
This is a summary of recent ratings and price targets for Relay Therapeutics and LadRx, as reported by MarketBeat.
据MarketBeat报道，这是Relay治疗公司和LadRx公司最近的评级和目标价摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Relay Therapeutics | 1 | 1 | 5 | 0 | 2.57 |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| 接力治疗学 | 1 | 1 | 5 | 0 | 2.57 |
| LadRx | 0 | 0 | 0 | 0 | 不适用 |
Relay Therapeutics presently has a consensus target price of $33.43, suggesting a potential upside of 62.43%. Given Relay Therapeutics' higher possible upside, equities research analysts clearly believe Relay Therapeutics is more favorable than LadRx.
Relay Treateutics目前的共识目标价为33.43美元，暗示潜在上涨62.43%。考虑到Relay治疗公司更高的可能上行空间，股票研究分析师显然认为Relay治疗公司比LadRx更有利。
Insider and Institutional Ownership
内部人与机构持股
0.1% of LadRx shares are held by institutional investors. 4.4% of Relay Therapeutics shares are held by company insiders. Comparatively, 12.8% of LadRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
LadRx 0.1%的股份由机构投资者持有。Relay Treateutics 4.4%的股份由公司内部人士持有。相比之下，LadRx 12.8%的股份由公司内部人士持有。强大的机构持股表明，对冲基金、捐赠基金和大型基金管理公司相信，一只股票有望实现长期增长。
Summary
摘要
LadRx beats Relay Therapeutics on 7 of the 12 factors compared between the two stocks.
在两只股票之间的12个因素中，LadRx在7个因素上击败了Relay Treateutics。
About Relay Therapeutics
关于接力疗法
(Get Rating)
(获取评级)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
接力治疗公司是一家临床阶段的精准药物公司。它致力于改变药物发现过程，最初的重点是在有针对性的肿瘤学和遗传病适应症中加强小分子治疗发现。该公司的主要候选产品包括RLY-4008，这是一种口服成纤维细胞生长因子受体2(FGFR2)小分子抑制剂，正在对晚期或转移性FGFR2改变的实体肿瘤患者进行首次人类临床试验；RLY-2608，一种针对磷酸肌醇3激酶α的领先突变体-PI3KA抑制剂计划；以及RLY-1971，一种口服蛋白酪氨酸磷酸酶同源区域2区域含磷酸酶-2的口服小分子抑制剂，正处于对晚期实体肿瘤患者的第一阶段试验。它与D.E.Shaw Research，LLC签订了合作和许可协议，通过使用D.E.Shaw Research专注于蛋白质运动分析的计算建模能力来研究某些生物靶标，以开发和商业化针对这些靶标的化合物和产品；以及Genentech，Inc.用于RLY-1971的开发和商业化。该公司前身为Alstery，Inc.，并于2015年12月更名为Relay Treateutics，Inc.。Relay治疗公司成立于2015年，总部设在马萨诸塞州剑桥市。
About LadRx
关于LadRx
(Get Rating)
(获取评级)
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LadRx公司是一家生物制药公司，致力于发现和开发治疗癌症患者的疗法。该公司正在进行后期临床试验的高级药物结合物醛阿霉素是抗癌药物阿霉素的一个版本。其临床前治疗包括针对癌症的连接子激活药物版本7、8、9和10。该公司前身为CytRx公司，并于2022年9月更名为LadRx公司。LadRx公司成立于1985年，总部设在加利福尼亚州洛杉矶。
Receive News & Ratings for Relay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《接力治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Relay Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。